Rose V. Thomas - Concepedia

Author

Rose V. Thomas

National Cancer Institute

Also Known As

R Thomas, R V Thomas, R.V. Thomas, ROSE V. THOMAS, Rose Thomas, Rose V Thomas, Rose V. Thomas, RoseV. Thomas

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health National Cancer Institute Abbott (United States)National Cancer Institute

About

Rose V. Thomas is an author at National Cancer Institute specializing in medicine, pharmacology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Health Sciences	1	1	32
3	Nursing	1	1	32
4	Public Health	1	1	20
5	Biochemistry	1	1	18

Rose V. Thomas

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine Robert Yarchoan, Hiroaki Mitsuya, Rose V. Thomas, Science	1989	425
Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases Raymond W. Klecker, Jerry M. Collins, Robert Yarchoan, Clinical Pharmacology & Therapeutics	1987	381
Suramin: an anticancer drug with a unique mechanism of action. C.A. Stein, R. V. Larocca, Rose V. Thomas, Journal of Clinical Oncology Tumor InnervationPathologyPharmacotherapyTumor BiologyDrug Resistance	1989	373
RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE Robert Yarchoan, Pim Brouwers, A R Spitzer, The Lancet NeurovirologyHuman RetrovirusAntiviral TherapyNeurologyAntiviral Drug	1987	356
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex Robert Yarchoan, James M. Pluda, Rose V. Thomas, The Lancet MedicineImmunologyLong-term Toxicity/activity ProfileToxicologyAntimicrobial Chemotherapy	1990	215
Pharmacokinetics of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in patients with severe human immunodeficiency virus infection Neil R. Hartman, Robert Yarchoan, James M. Pluda, Clinical Pharmacology & Therapeutics Therapeutic Drug MonitoringPlasma KineticsDrug InfusionAcquired Immunodeficiency SyndromeBioanalysis	1990	133
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex P de Miranda, Steven S. Good, Robert Yarchoan, Clinical Pharmacology & Therapeutics Short Half-lifePharmacologyImmunologyAntiviral TherapyPharmacotherapy	1989	117
Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders Raymond W. Klecker, Jerry M. Collins, Robert Yarchoan, The Journal of Clinical Pharmacology	1988	98
Long-term administration of 3?-Azido-2?,3?-dideoxythymidine to patients with AIDS-related neurological disease Robert Yarchoan, Rose V. Thomas, Jordan Grafman, Annals of Neurology	1988	88
Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex with a Regimen of 3′-Azido-2′,3′-Dideoxythymidine (Azidothymidine or Zidovudine) and Acyclovir Antonella Surbone, Robert Yarchoan, Nanette Mcatee, Annals of Internal Medicine Severe Hiv InfectionsHuman Immunodeficiency VirusAcquired Immunodeficiency SyndromeAids-related ComplexImmunodeficiencies	1988	70

Page 1